Finally, optimization of potency against the xCT antiporter aided by structure-activity relationship analysis (SAR) approach resulted in several derivatives that reduced cystine uptake when tested in a panel of cancer cell lines expressing xCT (20). Here, SLC7A11 is linked to cancer.